Most adults who stayed on tirzepatide for three years in the SURMOUNT-1 trial put back only a small part of what they had lost after reaching their lowest weight, according to a post hoc analysis published in Obesity Pillars. Of 690 participants with prediabetes who took at least three-quarters of their doses and lost at … Read more
The American Diabetes Association and the European Association for the Study of Diabetes have published their first update since 2022 of their joint consensus on managing type 2 diabetes, and it advocates using GLP-1-based drugs or SGLT2 inhibitors earlier, potentially from diagnosis, to protect the heart and kidneys. The report appeared in Diabetologia on 2 … Read more
When a state Medicaid programme starts paying for GLP-1 drugs labeled for obesity, the bill for those drugs goes up. A study in JAMA Health Forum suggests the net increase is smaller than that figure implies, because some of the new obesity-labeled prescriptions appear to replace diabetes-labeled versions of the same molecules, which every state … Read more
Prescriptions for GLP-1 receptor agonists written to US adults with no documented reason for taking them rose roughly 15-fold between 2021 and 2025, according to an analysis of electronic health records published on 22 September in Obesity. Among 92.4 million adults whose records showed neither type 2 diabetes nor obesity with a qualifying comorbidity, about … Read more
Novo Nordisk announced this morning that CagriSema, its investigational combination of semaglutide and a second hormone, beat tirzepatide on weight loss in a head-to-head phase 3 trial in adults with type 2 diabetes: an estimated 12.4% against 9.1% at week 60. A second phase 3 trial put CagriSema at 21.0% weight loss against 2.0% on … Read more
A 225-person tirzepatide trial in Japan has reported its metabolic detail, and one finding is unusually practical: across the treatment groups, the change in waist measurement tracked the change in visceral fat — the fat wrapped around the internal organs, and the kind that carries the metabolic risk — with a correlation of 0.84. Visceral … Read more
A systematic review has pulled together 26 economic evaluations of the approved weight-loss drugs, and the pattern it reports is worth knowing before anyone quotes “cost-effective” at you. Semaglutide came out ahead of liraglutide consistently enough that the authors call liraglutide generally not cost-effective. Tirzepatide bought the most health of any drug reviewed, and frequently … Read more
On September 18, 2026, the FDA issued a warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy, of Houston, Texas, following an inspection of its facility in November 2025. The agency said the pharmacy compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products that appear to be essentially copies of FDA-approved drugs — the legal line … Read more